Table 2.
Number of T cell reactive* and neutralizing study participants (n = 93)
| Number of reactive peptide pools | baseline neg | baseline pos | baseline - follow up | |||||
|---|---|---|---|---|---|---|---|---|
| p-p§ | p-d (NTpos) | p-d (NTneg) | p-a§ | p-n (NTpos) | p-n (NTneg) | |||
| 0 | 14/22 (63.6)# |
21/71 (29.6) |
4/28 (14.3) |
11/29 (37.9) |
4/9 (44.4) |
0/1 (0) |
1/3 (33.3) |
1/1 (100) |
| 1 | 5/22 (22.7) |
18/71 (25.4) |
8/28 (28.6) |
7/29 (24.1) |
1/9 (11.1) |
0/1 (0) |
2/3 (66.6) |
0/ 1 (0) |
| 2 | 3/22 (13.6) |
15/71 (21.1) |
7/28 (25.0) |
5/29 (17.2) |
3/9 (33.3) |
0/1 (0) |
0/3 (0) |
0/1 (0) |
| 3 | 0/24 (0) |
17/71 (23.9) |
9/28 (32.1) |
6/29 (20.7) |
1/9 (11.1) |
1/1 (100) |
0/3 (0) |
0/1 (0) |
* IFNγ+ SFCs / 106 cells > mean + 1 × SD of negative study participants
#
number of reactive samples/number of total samples (% reactive)
§
baseline – follow up serostatus p-p: positive - positive, p-d: positive - discordant, p-a: positive - IgA only, p-n: positive – negative, NTpos: neutralizing antibody positive (titer ≥1:16) at follow-up; NTneg: neutralizing antibody negative (titer ≤1:4) at follow-up